Just like urgent care centers, asynchronous medicine for patient queries could be great, or a disaster,” a STAT reader writes ...

The Medicines and Healthcare products Regulatory Agency (MHRA) has today, 23 October 2024, approved a license for the ...

Moving ahead, Rob Rowe, Regional Research Director and Head of Global Strategy at a large US bank is ‘ tactically bullish ’ on the back of continuing tech recovery and the markets “pricing in a soft ...

Tens of thousands of people will be recruited into Alzheimer’s trials after a landmark drug was rejected for use on the NHS.

The drug is the second Alzheimer’s medicine to receive a lukewarm reception from the UK government in recent months.View on ...

Expanding public education, increasing access and quality of care, supporting family caregivers and increasing training for ...

There have been many promising leads for an Alzheimer's vaccine but new treatments have been slow to merge. Researchers at ...

Though Lilly has been in the spotlight for the success of its GLP-1 drugs, the pharma giant has also been investing in a ...

Donanemab: What is the new Alzheimer’s drug rejected by the NHS? - Donanemab and another new drug for Alzheimer’s called ...

It marks the second such rejection in the UK for an Alzheimer’s treatment, after Eisai and Biogen’s drug met the same fate ...

Eli Lilly's donanemab receives UK approval for mild cognitive impairment and mild dementia due to Alzheimer's disease.

Donanemab marks a significant advancement in Alzheimer’s treatment, but NHS patients face a setback with NICE's rejection of ...